The country's first natural medicine has surpassed 600 billion won in cumulative sales since its launch in 2002.
SK Chemicals announced on the 25th that the cumulative sales of Joins Jung (hereinafter referred to as Joins) exceeded 600 billion won. This is the first time that a natural osteoarthritis treatment developed in Korea has surpassed 600 billion won in cumulative sales.
It achieved 100 billion won in additional sales in two years after achieving 400 billion won in cumulative sales in 2019 and 500 billion won in 2022.
Joins recorded 37.9 billion won in sales last year.
It occupies the highest share of herbal ingredient treatments in the SYMPTOMATIC Slow Doing Drugs for Osteoarthritis (SYSADOA) family arthritis treatment market, which is used to relieve symptoms over a long period of time as a symptom-improving drug for arthritis treatment.
"Join's has been sold for decades in the pharmaceutical industry, beyond marking a new milestone in R&D history, when the concept of natural products was unfamiliar," said Kim Yoon-ho, CEO of Pharma's business. "We will continue to strengthen our competitiveness in related markets based on our experience, know-how, and technology in the field of natural products and osteoarthritis."
[WIKI KOREA=Cho Pil Hyun, Staff Reporter]
chop23@wikileaks-kr.org
